Novo Nordisk CEO marks one year amid GLP-1 competition

Mike Doustdar said the 103-year-old Danish drugmaker is moving faster and looking outward after falling behind in the market it helped create.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.